Invention Grant
US09200058B2 Dual antagonist for TNF-α and IL-21 for preventing and treating autoimmune diseases
有权
用于预防和治疗自身免疫性疾病的TNF-α和IL-21的双重拮抗剂
- Patent Title: Dual antagonist for TNF-α and IL-21 for preventing and treating autoimmune diseases
- Patent Title (中): 用于预防和治疗自身免疫性疾病的TNF-α和IL-21的双重拮抗剂
-
Application No.: US13635874Application Date: 2011-03-18
-
Publication No.: US09200058B2Publication Date: 2015-12-01
- Inventor: Young Woo Park , Ki Won Jo , Srok Ho Yoo , Jung Yu , Sun-Ha Yoon , Ji Hyun Park , Eun Jung Song , Jong-Ho Lee , Min Ji Seo , Sun Jung Cho , Mi La Cho , Ho Youn Kim , Mi Kyung Park , Hye Jwa Oh , Jin Sil Park , Yun Ju Woo , Jae Kyeong Byun , Jun Geol Ryu
- Applicant: Young Woo Park , Ki Won Jo , Srok Ho Yoo , Jung Yu , Sun-Ha Yoon , Ji Hyun Park , Eun Jung Song , Jong-Ho Lee , Min Ji Seo , Sun Jung Cho , Mi La Cho , Ho Youn Kim , Mi Kyung Park , Hye Jwa Oh , Jin Sil Park , Yun Ju Woo , Jae Kyeong Byun , Jun Geol Ryu
- Applicant Address: KR Daejeon KR Seoul
- Assignee: Korea Research Institute of Bioscience and Biotechnology,Industry-Academic Cooperation Foundation, the Catholic University of Korea
- Current Assignee: Korea Research Institute of Bioscience and Biotechnology,Industry-Academic Cooperation Foundation, the Catholic University of Korea
- Current Assignee Address: KR Daejeon KR Seoul
- Agency: Lathrop & Gage LLP
- Priority: KR10-2010-0024700 20100319
- International Application: PCT/KR2011/001902 WO 20110318
- International Announcement: WO2011/115458 WO 20110922
- Main IPC: C07K14/715
- IPC: C07K14/715
Abstract:
The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.
Public/Granted literature
- US20130022642A1 Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases Public/Granted day:2013-01-24
Information query
